{
  "docId": "019de073-7e4e-7689-a01c-e0840dac2b61",
  "docSlug": "97e34d6c4db7d9454440fee3efd43545",
  "documentTitle": "Axcella Health | Results Presentation Deck | 62 slides",
  "authorId": "axcella-health",
  "authorName": "Axcella Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 21,
  "pageCount": 62,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 33,
  "notes": "DMC = Data Monitoring Committee; TEAE = Treatment Emergent Adverse Event; SAE = Serious Adverse Event.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7e4e-7689-a01c-e0840dac2b61/21",
  "deckHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61",
  "deckJsonHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61.json",
  "deckAnchorHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Safety based on what subject received on day 1 of dosing. DMC, independent data monitoring committee; SAE, serious adverse event; TEAEs, treatment emergent adverse events",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76989b10-ae21-43dc-8d39-5a0a5e0ebd43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.76
      },
      "kind": "list",
      "text": "Most frequent TEAEs are gastrointestinal; All SAEs and the death unrelated to study product; No safety or tolerability signals of concern were observed.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1dde9f7-088f-404b-9fb3-d3d2de2e5d09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.52,
        "w": 0.88,
        "x": 0.06,
        "y": 0.208
      },
      "kind": "table",
      "text": "Table comparing Placebo, AXA1125 22.6g BID, and AXA1125 33.9g BID across various safety metrics including TEAEs, severity grades, and SAEs.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85b8f9f9-54be-47f1-9aaa-2b2c9838cc06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Safety Interim Analysis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f2ae8b7-d57a-4dcb-b404-0cbf1100017a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Safety and Tolerability Remains Favorable Based on the Blinded Review",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f8b2f1f-1f72-4489-846b-c880642d3232",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 36,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "de6af44a-f17d-4c55-adca-ab6e25c41e5d",
      "evidence": "The presentation highlights the need for effective treatment options and the risks associated with disease progression",
      "position": 0,
      "objective": "What is the risk of not treating NASH effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}